Amorolfine (International)
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
D01AE16
CAS registry number (Chemical Abstracts Service)
0078613-35-1
Chemical Formula
C21-H35-N-O
Molecular Weight
318
Therapeutic Category
Antifungal agent for topical use
Chemical Name
(±)-cis-2,6-Dimetyl-4-[2-metyl-3-(p-tert-pentylphenyl)propyl]morpholine (WHO)
Foreign Names
- Amorolfinum (Latin)
- Amorolfin (German)
- Amorolfine (French)
- Amorolfina (Spanish)
Generic Names
- Amorolfine (OS: BAN, DCF, USAN)
- Ro 14-4767/000 (Roche) (IS)
- Ro 14-4767/002 (Roche) (IS)
- Amorolfine Hydrochloride (OS: BANM, JAN)
- Amorolfine Hydrochloride (PH: BP 2018)
- Amorolfine hydrochloride (PH: Ph. Eur. 9)
Brand Names
- Amofin
Belupo, Croatia (Hrvatska) - Amorolfin-Teva 50 mg/ml
Teva, Hungary - Arivil
Farmal, Croatia (Hrvatska) - Dermoceryl
EMS, Brazil - Fental
Sieger Pharma, Greece - Fungilac
Farmal, Croatia (Hrvatska) - Funtrol
Axxon, Poland; Chanelle Medical, Romania; Polta, Lithuania - Loceryl
Galderma, Argentina; Galderma, Hong Kong; Galderma, India; Galderma, Malaysia; Galderma, Peru; Galderma, Uruguay; Galderma Chile Laboratorios, Chile; Galderma Laboratories, South Africa; Lex ano, Lithuania - Loceryl 5%
Eczacibasi Ilac Pazarlama, Turkey; Galderma, Cyprus - Loceryl 50 mg/ml
Galderma, Hungary - Loceryl Amorolfine
Galderma, Tunisia - Locetar
Galderma, Philippines - Lomytrat
Legrand/OTC, Brazil - Myconail
AFT, New Zealand - Myconolak
Axxon, Poland - Neolaque
Chanelle Medical, Serbia - Razole
Bilim, Turkey - Amocoat
Hwang's, Taiwan - Amofin 5%
Galenpharma, Germany - Amorocutan
Dermapharm, Germany - Amorocutan 50mg/ml
Dermapharm, Austria; Dermapharm, Switzerland - Amorolak
Sun-Farm, Poland - Amorolfin ABECE
Evolan, Sweden - Amorolfin AL 5%
Aliud Pharma, Germany - Amorolfin Apofri
Apofri, Sweden - Amorolfin Heumann
Heumann, Germany - Amorolfin Mylan
Mylan, Sweden - Amorolfin Ratiopharm 5%
Ratiopharm GmbH, Iceland - Amorolfin STADA 5%
Stada Arzneimittel, Germany - Amorolfina Adoh
Adoh, Spain - Amorolfina Ciclum
Ciclum, Portugal - Amorolfina Generis
Generis, Portugal - Amorolfina Isdin
Isdin, Spain - Amorolfina Mylan
Mylan, Spain; Mylan, Portugal - Amorolfina ratiopharm
Ratiopharm, Portugal - Amorolfina Stada
STADA, Spain - Amorolfina Teva
Teva, Spain; Teva Pharma, Portugal - Amorolfina Zentiva
Zentiva, Portugal - Amorolfin-CT 5%
AbZ-Pharma, Germany - Amorolfine 5%
Reckitt Benckiser Healthcare UK, United Kingdom - Amorolfine 5% Actavis
Actavis UK, United Kingdom - Amorolfine 5% Aspire
Aspire Pharma, United Kingdom - Amorolfine 5% Zentiva
Zentiva, United Kingdom - Amorolfine Arrow 5%
Arrow, France - Amorolfine BGR 5%
Biogaran, France - Amorolfine Biogaran Conseil 5 %
Biogaran, France - Amorolfine Chanelle
Chanelle Medical, Hong Kong - Amorolfine Cristers 5%
CristerS, France - Amorolfine EG 5%
EG Labo, France - Amorolfine EG Labo Conseil 5 %
EG Labo, France - Amorolfine Hydrochloride 5%
Stada Arzneimittel, United Kingdom - Amorolfine Mylan 5%
Mylan, France - Amorolfine Mylan Conseil 5 %
Mylan, France - Amorolfine Pierre Fabre
Pierre Fabre, Sweden - Amorolfine Pierre Fabre 5%
Pierre Fabre Dermatologie, France - Amorolfine Ranbaxy 5%
Ranbaxy, France - Amorolfine Sandoz
Sandoz, Taiwan - Amorolfine Sandoz 5%
Sandoz, France - Amorolfine Sandoz Conseil 5 %
Sandoz, France - Amorolfine Teva 5%
Teva Pharma Belgium, Belgium; Teva Santé, France - Amorolfine Urgo 5%
Urgo, France - Amorolfine Zentiva 5%
Sanofi Aventis, France - Amorolfine Zydus 5%
Zydus, France - Amorolfin-Mepha 5%
Mepha Pharma, Switzerland - Amorolfin-ratiopharm 5%
ratiopharm, Germany - Aporyl
Apotex, Australia - Avoza
UBI, Taiwan - Boots Once Weekly Fungal Nail Treatment 5%
The Boots Company, United Kingdom - Care Antifungal 5%
Thornton & Ross, United Kingdom - Chemists' Own Amer-Fine
Arrow Pharmaceuticals, Australia - Clavusimyl 5%
Generics UK, United Kingdom - Curanail
Galderma, Ireland - Curanail 5%
Galderma Benelux, Belgium - Curanel 50mg/ml
Galderma Schweiz, Switzerland - Finail
Orifarm Generics, Denmark; Orifarm Generics, Sweden - Fungilac
Jadran, Bosnia & Herzegowina - Fung-X 50 mg/ml
Axapharm, Switzerland - Laquifun
Panalab, Argentina - Loceryl
Actavis Group, Malta; Galderma, Austria; Galderma, Australia; Galderma, Bahrain; Galderma, Brazil; Galderma, China; Galderma, Czech Republic; Galderma, Ecuador; Galderma, Estonia; Galderma, Greece; Galderma, Ireland; Galderma, Lebanon; Galderma, Lithuania; Galderma, Latvia; Galderma, Mexico; Galderma, Norway; Galderma, New Zealand; Galderma, Poland; Galderma, Singapore; Galderma, Thailand; Galderma, Taiwan; Galderma, Venezuela; Galderma Nordic, Denmark; Galderma Nordic, Sweden; Galderma Nordic AB, Iceland; Laboratoires Galderma, Israel - Loceryl 0,25%
Galderma, Germany - Loceryl 2.5 mg/g
Galderma, Hungary - Loceryl 5%
Galderma, France; Galderma, Luxembourg; Galderma, Slovakia; Galderma Benelux, Belgium; Galderma Nordic AB, Finland; Galderma U.K., United Kingdom - Loceryl Curanail 5%
Galderma U.K., United Kingdom - Locetar
Galderma, Spain; Galderma, Portugal; Galderma Italia, Italy - Micocide A
Atlas Farmc., Argentina; Mediderm, Chile - Myconail
AFT Pharmaceuticals, Australia - Myconxin
Root, Taiwan - Nailcure Sandoz 50mg/ml
Sandoz, Switzerland - Neolaque 50 mg/ml
PharmaSwiss, Hungary - Odenil
Galderma, Spain - Onicoryl
Germed Farmaceutica, Brazil - Pekiron
Shinlin Sinseng, Taiwan - Pekiron 0.5%
Galderma, Japan - Pharmacy Action Antifungal Nail Treatment
Generic Health, Australia - Sanail-Mepha once a week 50mg/ml
Mepha Pharma, Switzerland - Sandoz Nail Repair
Sandoz, Australia - Schollmed once weekly 5%
Reckitt Benckiser Healthcare UK, United Kingdom - Sinibal
Atral, Portugal
Glossary
Term | Definition |
---|---|
BAN | British Approved Name |
BANM | British Approved Name (Modified) |
DCF | Dénomination Commune Française |
IS | Inofficial Synonym |
JAN | Japanese Accepted Name |
OS | Official Synonym |
PH | Pharmacopoeia Name |
Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
USAN | United States Adopted Name |
WHO | World Health Organization |
Further information on drug naming conventions: International Nonproprietary Names.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.